Drug Profile
Research programme: cardiovascular disease and diabetes therapeutics - Bristol-Myers Squibb/Celera Diagnostics
Latest Information Update: 03 Aug 2010
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Celera Diagnostics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Diabetes mellitus
Most Recent Events
- 21 Jan 2008 Preclinical development is ongoing
- 10 Aug 2007 Preclinical development is ongoing
- 01 Jan 2006 Celera Diagnostics has been acquired by Celera Genomics Group